Retatrutide vs Semaglutide

Side-by-side comparison of Retatrutide, Semaglutide — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Retatrutide Retatrutide (GIP/GLP-1/Glucagon Triple Agonist) Weight Loss Semaglutide Semaglutide (GLP-1 Receptor Agonist) Weight Loss
Basics
Molecular type Triple GIP/GLP-1/Glucagon Receptor AgonistGLP-1 Receptor Agonist
Amino acids —31
Molecular weight —4,113.6 Da
Half-life ~6 days~7 days
Route(s) Subcutaneous injectionSubcutaneous injection, Oral (Rybelsus)
Mechanism & Research
Primary mechanism Retatrutide activates three incretin and metabolic hormone receptors simultaneously. GLP-1 receptor agonism drives appetite suppression, slows gastric emptying, and reduces food intake — the primary mechanism shared with… Semaglutide binds and activates GLP-1 receptors throughout the body with high affinity. In the pancreas, it stimulates glucose-dependent insulin secretion and suppresses glucagon release. These effects are glucose-depend…
Research status Phase 3 Trial FDA Approved
Evidence summary Retatrutide is in Phase 3 clinical trials (NCT06052826) as of 2026, following highly positive Phase 2 data. The Phase 2 trial (NCT04881760, n=338) is the strongest weight loss signal from any pharmacological agent in hum… Semaglutide has one of the most robust clinical trial programmes of any peptide compound. The STEP trial series (for weight management) and SUSTAIN series (for diabetes) collectively enrolled tens of thousands of partici…
Protocol & Dosing
Typical dose 2mg → 12mg weekly (titration)0.25mg → 2.4mg weekly (weight management)
Frequency Once weeklyOnce weekly
Duration Ongoing (Phase 3)Ongoing (chronic management)
Timing Same day each weekSame day each week, any time
Safety
Common side effects
  • Nausea
  • Vomiting
  • Diarrhoea
  • Constipation
  • Nausea (44%)
  • Diarrhoea (30%)
  • Vomiting (24%)
  • Constipation (24%)
Contraindications
  • History of MEN2 or medullary thyroid carcinoma
  • Active pancreatitis
  • Pregnancy
  • Personal/family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia type 2 (MEN2)
  • Pancreatitis history
Anti-doping Not Prohibited Not Prohibited
Deeper reading
Related peptides Tirzepatide, Semaglutide, AOD-9604 Tirzepatide, AOD-9604, Tesamorelin
Full profile Read full Retatrutide profile → Read full Semaglutide profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.